Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Q1 2018/19 Earnings Presentation
9 slides from Coloplast A/s Class B's earnings presentation, Feb 5, 2019
Slide 1: Coloplast Earnings Conference Call Q1 2018/19
Coloplast Earnings Conference Call Q1 2018/19 5 February 2019
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Getting started and initial priorities by CEO Kristian Villumsen
Getting started and initial priorities by CEO Kristian Villumsen LEAD 20 strategy Long-term guidance Revenue growth annual organic 7–9% EBIT margin constant currencies >30% Page 3
Slide 4: Solid start to the year with 8% organic growth in Q1 and guidance for 2018/19 maintained
Solid start to the year with 8% organic growth in Q1 and guidance for 2018/19 maintained Q1 2018/19 Highlights Revenue growth • Organic growth of 8% (9% reported growth in DKK) driven by Reported revenue (DKKm) +8% strong momentum across all business areas and geographies Organic growth +9% • Acquis
Slide 5: Solid growth across all business areas and geographical regions
Solid growth across all business areas and geographical regions Q1 18/19 revenue by business area Q1 18/19 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm growth Ostomy Care 1,736 8%
Slide 6: Q1 18/19 reported revenue grew 9% driven by solid organic growth of 8%
Q1 18/19 reported revenue grew 9% driven by solid organic growth of 8% Comments Revenue development • Q1 2018/19 reported revenue increased by DKK 366m (DKKm) 55 or 9% compared to Q1 2017/18 4,321 -11 • The majority of growth was driven by organic growth 322 contributing DKK 322m or 8% to reported r
Slide 7: EBIT grew 8% in Q1 corresponding to an EBIT margin of 30%
EBIT grew 8% in Q1 corresponding to an EBIT margin of 30%, negatively impacted by higher admin and restructuring costs Comments EBIT margin development (%) • EBIT increased 8% to DKK 1,297m with a reported margin of 30% compared to 31% last year • Gross margin of 67% in DKK compared to 67% same peri
Slide 8: Unchanged guidance for FY 2018/19
Unchanged guidance for FY 2018/19 Guidance 2018/19 Guidance 2018/19 (DKK)* Key assumptions Sales growth ~8% • Up to 1% negative price pressure 8-9% (organic) • DKK guidance includes growth from Lilial and IncoCare • Incremental investments of up to 2% of revenue • Restructuring costs of DKK 35m from
Slide 9: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /